Comparison of the antiarrhythmic and the proarrhythmic effect of almokalant in anaesthetised rabbits

European Journal of Pharmacology

Volumn 346, Issue 2-3, 1998, Pages 245-253

  Farkas, András ^a   Leprán, István ^a   Papp, Julius Gy ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

(Anaesthetised rabbit); Almokalant; Antiarrhythmic effect; Proarrhythmia; Reperfusion arrhythmias; Torsade de pointes

Indexed keywords

ALMOKALANT; PENTOBARBITAL;

ALPHA ADRENERGIC STIMULATION; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HEART MUSCLE REPERFUSION; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ADRENERGIC ALPHA-AGONISTS; ANESTHESIA; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BLOOD PRESSURE; CORONARY VESSELS; FEMALE; HEART; HEART RATE; MALE; MYOCARDIAL REPERFUSION INJURY; PHENYLEPHRINE; PROPANOLAMINES; RABBITS; TORSADES DE POINTES;

EID: 0032502603     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00067-3     Document Type: Article

References (42)

1. K blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc. Res. 27:1993;861-867.
2. Bayes de Luna A., Coumel P., LeClerq J.R. Ambulatory sudden cardiac death: Mechanism of production on the basis of data from 157 cases. Am. Heart J. 117:1989;151-162.
3. Bril A., Gout B., Bonhomme M., Landais L., Faivre J.F., Linne P., Poyser R.H., Ruffolo R.R. Jr. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmia risk: Experimental profile of BRL-32872. J. Pharmacol. Exp. Ther. 276:1996;637-646.
4. Buchanan L.V., Kabell G., Brunden M.N., Gibson J.K. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, UK-68,798 in a rabbit model of proarrhythmia. J. Cardiovasc. Pharmacol. 220:1993;540-549.
5. The Cardiac Arrhythmia Suppression Trial (CAST) investigators, 1989. Preliminary report: effect of encainide and flecainide on mortality in randomized and trial of arrhythmia suppression after myocardial infarction. New Engl. J. Med. 321, 406-412.
6. Carlsson L., Almgren O., Duker G. QTU prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol. 16:1990;276-285.
7. Carlsson L., Abrahamsson C., Andersson B., Duker G., Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate QT dispersion, and early afterdepolarisations. Cardiovasc. Res. 27:1993;2186-2193.
8. Carlsson L., Drews L., Duker G., Schiller-Linhardt G. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J. Pharmacol. Exp. Ther. 267:1993;1076-1080.
9. 2+ overload. J. Pharmacol. Exp. Ther. 279:1996;231-239.
10. Chen J., Xue Y., Eto K., Ni C., Hashimoto K. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs. J. Cardiovasc. Pharmacol. 28:1996;576-584.
11. + channel blockers and activators in cardiac arrhythmias. Cardiovasc. Drug. Rev. 7:1989;199-209.
12. Coronel R., Wilms-Schopman F.J., Opthof T., Cinca J., Fiolet J.W., Janse M.J. Reperfusion arrhythmias in isolated perfused pig hearts. Inhomogeneities in extracellular potassium, ST and TQ potentials, and transmembrane action potentials. Circ. Res. 71:1992;1131-1142.
13. Cranefield P.F., Aronson R.S. Torsades de pointes and other pause induced ventricular tachycardias: the short-long-short sequence and early afterdepolarisations. Pace. 11:1988;670-678.
14. Crijns H., Meeder J., Van-Gelder I., Wiesfeld A., Svernhage E., Ebels T. Effect of almokalant in atrial fibrillation and flutter. Pacing Clin. Electrophysiol. 18:1995;798.
15. Darpö B., Edvardsson N. Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group. J. Cardiovasc. Pharmacol. 26:1995;198-206.
16. Darpö B., Allared M., Edvardsson N. Torsades de pointes induced by transesophageal atrial stimulation after administration of almokalant. Int. J. Cardiol. 53:1996;311-313.
17. Duker G., Almgren O., Carlsson L. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog. J. Cardiovasc. Pharmacol. 20:1992;458-465.
18. Hallman K., Carlsson L. Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. Pharmacol. Toxicol. 77:1995;250-254.
19. Hayashi H., Terada H., McDonald T.F. Electrical heterogeneity and conduction block in reoxygenated guinea pig papillary muscles. Jpn. Heart J. 37:1996;383-391.
20. Hohnloser S.H., Singh B.N. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J. Cardiovasc. Electrophysiol. 6:1995;920-936.
21. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686-690.
22. Jackman W.M., Friday K.J., Anderson J.L., Aliot E.M., Clark M., Lazzara R. The long QT syndromes: A critical review, new clinical observations and unifying hypothesis. Prog. Cardiovasc. Dis. 31:1988;115-172.
23. Katritsis D., Camm A.J. New class III antiarrhythmic drugs. Eur. Heart J. 14(Suppl. H):1993;93-99.
24. Kowey P.R., VanderLugt J.T., Luderer J.R. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am. J. Cardiol. 78:1996;46-52.
25. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur. Heart J. 14:1993;88-92. Suppl H.
26. Leprán I., Koltai M., Siegmund W., Szekeres L. Coronary artery ligation, early arrhythmias and determination of the ischaemic area in conscious rats. J. Pharmacol. Methods. 9:1983;219-230.
27. Maxwell M.P., Hearse D.J., Yellon D.M. Species variation in the collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc. Res. 21:1987;737-746.
28. Pasnani J.S., Ferrier G.R. Pro- and antiarrhythmic effects of D-sotalol and DL-sotalol in an isolated tissue model of ischemia and reperfusion. J. Pharmacol. Exp. Ther. 271:1994;184-192.
29. Pogwizd S.M., Corr B. The contribution of nonreentrant mechanisms to malignant ventricular arrhythmias. Basic Res. Cardiol. 87:1992;115-129. Suppl 2.
30. K blockade as an antiarrhythmic mechanism: effects of UK66,914 on ischaemia and reperfusion arrhythmias in rat and rabbit hearts. Br. J. Pharmacol. 108:1993;139-145.
31. Roden D.M. Current status of class III antiarrhythmic drug therapy. Am. J. Cardiol. 72:1993;44B-49B.
32. Roden D.M., Woosely R.L., Primm R.K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am. Heart J. 111:1986;1088-1093.
33. Soffer J., Dreifus L.S., Michelson E.L. Polymorphous ventricular tachycardia associated with normal and long QT intervals. Am. J. Cardiol. 49:1982;2021-2029.
34. Thiemermann C., Thomas G.R., Vane J.R. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. Br. J. Pharmacol. 97:1989;401-408.
35. Toyo-oka T., Kamishiro T., Fumino H., Masaki T., Hosoda S. Rabbit hearts for the critical evaluation of drugs to reduce the size of experimentally produced acute myocardial infarction. Jpn. Heart J. 25:1984;623-632.
36. Verduyn S.C., Vos M.A., Van der Zande J., Wellens H.J. A comparison between the proarrhythmic effect of almokalant and D-sotalol in an animal model of torsade de pointes arrhythmia. J. Am. Coll. Cardiol. 170A:1995.
37. Vos M.A., Verduyn S.C., Gorgels A.P., Lipcsei G.C., Wellens H.J. Reproducible induction of early afterdepolarisations and torsade de pointes arrhythmias by D-sotalol and pacing in dogs with chronic atrioventricular block. Circulation. 91:1995;864-872.
38. Walker M.J.A., Curtis M.J., Hearse D.J., Campbell R.W.F., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W.G.et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction and reperfusion. Cardiovasc. Res. 22:1988;447-455.
39. Wettwer E., Grundke M., Ravens U. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc. Res. 26:1992;1145-1152.
40. Wiesfeld A.C., Crijns H.J., Bergstrand R.H., Almgren O., Hillege H.L., Lie K.I. Torsades de pointes with Almokalant, a new class III antiarrhythmic drug. Am. Heart. J. 126:1993;1008-1011.
41. Wiesfeld A.C., Crijns H.J., Tobe T.J., Almgren O., Bergstrand R.H., Aberg J., Haaksma J., Lie K.I. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias. Am. J. Cardiol. 70:1992;990-996.
42. Xue Y.X., Eto K., Akie Y., Hashimoto K. Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models. Jpn. J. Pharmacol. 70:1996;129-138.